Victoria Socha

DocwireNews

American Society of Transplant Surgeons Winter Symposium 2021End-stage kidney disease is commonly treated with kidney transplantation. However, the number of patients on the waitlist for transplant is significantly higher than the number of available donor organs; in 2019, there were approximately 95,000 patients on the waitlist to receive a kidney allograft.According to Obi Davies-Ekwenna, MD, of the University of Toledo Medical Center, Ohio, the donor pool could be increased with the use of high Kidney Door Profile Index (KDPI) organs as well as kidneys from small pediatric donors (en bloc). In those situations, dual kidney transplant may be associated with the best outcomes.High KDPI organs have shorter graft survival times compared with low KDPI allografts. By identifying early signs of rejection, injury, and graft dysfunction, close monitoring may improve 1-year outcomes in patients receiving high KDPI organs. Donor derived cell-free DNA (dd-cfDNA) is an established biomarker for monitoring <a href="https://www.docwirenews.com/nephtimes/nephtimes-features/nephtimes-focus-on-transplantation/incorporation-of-dd-cfdna-testing-in-clinical-practice/">allograft</a> rejection in kidney transplant recipients.Dr. Ekwenna et al. conducted a retrospective analysis on data from nine patients who received dual or en bloc kidney transplants. Results of the analysis were reported during a virtual poster session at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium in a <a href="https://asts.org/events-meetings/winter-symposium#.YEeD5F1Kiko">poster</a> titled Serial Testing with Donor-Derived Cell-Free DNA Test to Monitor Dual and en Bloc Kidney Transplants for signs of Rejection.In each patient, dd-cfDNA fractions were measured 2 to 3 weeks post-transplant using Prospera,&trade; a single nucleotide polymorphism (SNP)-based massively multiplexed PCR (mmPCr) assay. Four of the nine patients had elevated levels of dd-cfDNA.Of those four, one patient experienced delayed graft function requiring dialysis, and one experienced thrombotic complications that required resection of one allograft. There was no clinical reason found for increased dd-cfDNA in the third patient; at a subsequent test 10 days later, dd-cfDNA decreased 1.7 times. The patient&rsquo;s dd-cfDNA levels are being monitored. The fourth patient experienced an increase in dd-cfDNA level. Biopsy revealed acute cellular rejection; the patient was treated with thymoglobulin and steroids and ultimately had rejection of the allograft.All other patients are stable and undergoing serial monitoring.&ldquo;Dual and en bloc kidney transplants present unique situations where increased allograft volume or other factors not yet defined may contribute to increased basal levels of dd-cfDNA. Our early experience using dd-cfDNA to monitor dual/en bloc transplant recipients suggests that serial tests, starting early, can indicate allograft health,&rdquo; the researchers said.Source: Davies-Ekwenna O, Brown ML, McCormick S, et al. Serial testing with donor-derived cell-free DNA test to monitor dual and en bloc kidney transplants for signs of rejection. Poster presented at the American Society of Transplant Surgeons virtual 21st Annual State of the Art Winter Symposium (E-poster 118), January 14, 2021. Support for this study was provided by Natera, Inc.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Monitoring Dual and en Bloc Kidney Transplant Patients for Allograft Rejection

Kidney Transplantation

American Society of Transplant Surgeons Winter Symposium 2021 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe